Gamma-aminobutyric acid type A receptor subunit beta (GABAA receptor beta subunit)

The GABA-A receptor subunit beta is one of the principal subunits forming the gamma-aminobutyric acid type A (GABA-A) receptor, a pentameric ligand-gated chloride ion channel mediating fast synaptic inhibition in the mammalian central nervous system[1][3][7]. There are three known beta subunits in humans (β1, β2, β3; genes GABRB1, GABRB2, GABRB3), each ~450 amino acids in length, organized with a large extracellular N-terminal domain and four transmembrane domains[3][5]. Along with α and usually γ subunits, β subunits contribute to the physiological and pharmacological diversity of GABA-A receptors, influencing the affinity and response to endogenous GABA and numerous clinically important drugs including benzodiazepines, barbiturates, anesthetics, neurosteroids, and certain anticonvulsants[2][7][8]. Alterations in the function or expression of GABA-A receptor beta subunits are implicated in a variety of neurological and psychiatric diseases, especially epilepsy, anxiety, and certain neurodevelopmental and neurodegenerative disorders[4][7]. Recent studies have also revealed potential for proton-activated gating when certain beta subunits form homomeric receptors, expanding their functional repertoire[5]. Because of this diversity and central role in inhibitory neurotransmission, GABA-A receptor beta subunits are prominent therapeutic targets, but present challenges including risks of sedation, dependence, tolerance, and cognitive side effects when pharmacologically modulated[2][4][6][8].

Other names

GABA-A receptor beta subunitGABAA receptor β subunitGABAA β1 (or β2, β3) subunit (gene names GABRB1, GABRB2, GABRB3)Beta subunit of GABA(A) receptor

Positive allosteric modulation (increases the effect of GABA binding; anxiolytics, sedatives, anticonvulsants, hypnotics)[2][4][6]; Negative allosteric modulation (reduces the effect of GABA binding)[2]; Direct agonism (at high concentrations for some anesthetics or specific subunit compositions)[8]; Proton-activated gating (for certain β subunit homomers, newly described)[5]; Selective subunit targeting for specific therapeutic actions (e.g., anxiolysis, memory enhancement)[2][6].